Foresite Capital Management IV, LLC
Annual return '25
+17.1%
SPY '25
+17.7%
Alpha
-0.7ptsvs SPY
Invested
$1.2B
Holdings
8
Trades YTD
0
Performance · Fund vs SPY
Cumulative return · quarterly snapshotsCoverage 100%. 4 quarters of 2025 measured against SPY adj-close benchmark.
Top holdings · current snapshot
Source: 13F-HR01
$PHVS
Pharvaris N.V.
Q3 2025: Increased +8.3% (4.41M → 4.78M shares)
56.9%
02
$CYTK
CYTOKINETICS INC
Q3 2025: New position (458.3k shares)
14.0%
03
$EIKN
Eikon Therapeutics, Inc.
Held since at least Q1 2024
8.7%
04
$LYEL
Lyell Immunopharma, Inc.
Q2 2025: New position (800.4k shares)
6.8%
05
$RLAY
Relay Therapeutics, Inc.
Q4 2024: New position (1.00M shares)
4.2%
06
$XENE
Xenon Pharmaceuticals Inc.
Q2 2025: New position (160.0k shares)
3.9%
07
$ALEC
Alector, Inc.
Held since at least Q1 2024
3.5%
08
$MAZE
Maze Therapeutics, Inc.
Q3 2025: Sold 75.2% (2.11M → 522.7k shares)
2.0%
Recent trades · Last 90 days
No Form 4 / 13D / 13G trade events on file in the recent window. 13F filers report position snapshots quarterly rather than per-trade events, so this section is most useful for managers who also file Form 4 or 13D/G.
Convergence · Pattern Engine ships in v1.1
30-day windowIn development
Convergence participation lands with the Pattern Engine.
Once the Pattern Engine ships, this section will list every active convergence event this fund is named in — with the other named funds, the Congress members on the same name, and combined position size.
Source data: SEC EDGAR · 13F-HR filings · Performance through 2025-12-31 · Last refreshed 10:11 UTC.